Semaglutide vs Retatrutide: The Phase 3 Data Compared

Retatrutide produces more weight loss than semaglutide, but only semaglutide is approved: counting everyone randomized, retatrutide 12 mg produced 25.0% weight loss at 80 weeks in TRIUMPH-1 against 14.9% for semaglutide 2.4 mg at 68 weeks in STEP 1. No head-to-head trial exists, so that gap is cross-trial. This review sets the two molecules side by side on receptor pharmacology, Phase 3 outcomes, tolerability, and regulatory status so readers can see where hype ends and evidence begins.

Key takeaways#

• Semaglutide is a single-target GLP-1 receptor agonist approved for weight management and cardiovascular risk reduction. Retatrutide is an investigational triple agonist hitting GLP-1, GIP and glucagon receptors.
• In its pivotal STEP 1 trial, semaglutide 2.4 mg produced a mean 14.9% weight reduction at 68 weeks versus 2.4% for placebo, counting everyone randomized.
• In TRIUMPH-1, published in NEJM in September 2026, retatrutide 12 mg produced a mean 25.0% weight reduction at 80 weeks on the same treatment-regimen basis (28.3% among participants who stayed on treatment), with 30.3% at 104 weeks in the BMI ≥35 extension.
• Semaglutide has a completed cardiovascular outcomes trial (SELECT). Retatrutide does not: its outcomes trial is TRIUMPH-Outcomes, still running, and the July 2026 TRIUMPH-3 weight trial in cardiovascular patients did not show a reduction in events.
• Both molecules share a gastrointestinal-heavy adverse event profile. Retatrutide adds a dysesthesia signal and a larger heart-rate increase.

The pharmacology gap explains the efficacy gap#

Semaglutide and retatrutide are often lumped into the same "GLP-1 category" in consumer coverage. That framing hides the mechanism.

Semaglutide is a mono-agonist. It binds the GLP-1 receptor, slowing gastric emptying, amplifying glucose-dependent insulin secretion, and reducing appetite via central pathways. That single-target action drives its efficacy ceiling.

Retatrutide is structurally different. It targets glucose-dependent insulinotropic polypeptide receptors, glucagon-like peptide-1 receptors and glucagon receptors. The added glucagon receptor engagement is the mechanistic twist most consumer content misses. Glucagon receptor activity raises energy expenditure and mobilises hepatic lipid stores, which is why the liver-fat data on retatrutide (discussed below) is unusually strong. The paired GIP and GLP-1 action, meanwhile, is what tirzepatide already validated, so retatrutide is best thought of as tirzepatide with an added glucagon arm.

The receptor stack is why the weight-loss numbers diverge. Research suggests the two peptides are not in the same efficacy tier despite the shared "incretin" family label.

Cross-trial weight loss data favors retatrutide by roughly ten points#

The cross-trial comparison is not perfectly matched (different populations, different durations, no head-to-head study yet exists), but the magnitude of the difference is large enough to survive the caveat.

For semaglutide, the reference is STEP 1. Participants who received semaglutide 2.4 mg had a mean change in body weight of −14.9% after 68 weeks compared with −2.4% in the placebo group, and 86% of treated participants attained at least a 5% reduction in total body weight. Follow-on data from the 104-week STEP 5 trial showed the mean weight loss with semaglutide 2.4 mg at weeks 52 and 104 was −15.6% and −15.2% respectively, suggesting minimal weight regain over 104 weeks when treatment is continued.

For retatrutide, the reference is now TRIUMPH-1, published in NEJM in September 2026. On the primary treatment-regimen estimand, which like STEP 1 counts everyone randomized, mean weight change at 80 weeks was −17.6% at 4 mg, −23.7% at 9 mg and −25.0% at 12 mg versus −3.9% on placebo. Lilly's press releases lead with the efficacy estimand (participants who stayed on treatment): 19.0%, 25.9% and 28.3%. Those with a starting BMI of 35 or higher who continued on the drug lost up to 30.3% (an average 85.0 lbs) at 104 weeks, and the 4 mg arm had a discontinuation rate lower than placebo. That 4 mg number is notable: even the lowest tested dose of retatrutide (17.6%) came in above semaglutide's headline STEP 1 result (14.9%) on the same estimand, across separate trials.

On the efficacy estimand, 45.3% of the 12 mg group lost 30% or more of their body weight, an outcome typically associated with weight loss surgery, which puts retatrutide among the few pharmacological candidates to approach bariatric-surgery territory.

Cardiovascular and metabolic outcomes remain semaglutide's strongest card#

Weight loss is a surrogate. Hard cardiovascular endpoints are what regulators and payers eventually anchor to, and semaglutide already has that dossier.

In the SELECT trial, once-weekly semaglutide 2.4 mg was associated with a statistically significant 20% reduction in major adverse cardiovascular events compared with placebo. The full SELECT publication in the New England Journal of Medicine confirmed superiority for the composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke at a mean follow-up of 39.8 months. Long-term follow-up analyses have also shown sustained weight loss and additional renal benefit, with studies have shown a 22% lower risk for kidney-related outcomes in the SELECT population.

Retatrutide has no completed cardiovascular outcomes trial yet. Its dedicated outcomes trial, TRIUMPH-Outcomes, is still running. TRIUMPH-3, which enrolled adults with severe obesity and established cardiovascular disease, read out in July 2026 as a weight trial (up to 22.6% versus 3.2% on placebo at 80 weeks, efficacy estimand); its prespecified cardiovascular analyses were underpowered and did not show fewer events (MACE-3 hazard ratio 1.12, 95% CI 0.64 to 1.96), per Lilly's topline release. So while retatrutide's cardiometabolic biomarker data looks strong, the hard-outcomes evidence base is still asymmetrical in semaglutide's favor.

On liver fat, retatrutide has the more striking preclinical-to-clinical continuum. In a Phase 2a substudy, the mean relative change from baseline in liver fat at 24 weeks was −42.9%, −57.0%, −81.4% and −82.4% for the 1, 4, 8 and 12 mg doses respectively (all P < 0.001 versus placebo), with normal liver fat achieved by 86% of participants on the 12 mg dose. Semaglutide's MASH readouts are also positive but the effect size is smaller.

Tolerability and side effect profiles overlap but not identically#

Both peptides share the gastrointestinal signature that defines the incretin class.

For semaglutide, the STEP 1 safety analysis showed the most common adverse events among subjects treated with semaglutide 2.4 mg were gastrointestinal events, most of which were transient and mild or moderate in severity. In SELECT, adverse events leading to permanent discontinuation of the trial product occurred in 16.6% of the semaglutide group versus 8.2% of placebo, which is the more realistic real-world tolerability signal.

Retatrutide's GI profile is broadly similar in kind, and its trials use a stepwise escalation from 2 mg to keep tolerability acceptable at the 9 mg and 12 mg doses; in TRIUMPH-1, adverse events led to discontinuation in 11.3% of the 12 mg group versus 4.9% on placebo. Retatrutide also introduces two watch-items that go beyond semaglutide's profile: a dose-dependent rise in resting heart rate that is larger than the 1 to 4 bpm on the Wegovy label, and dysesthesia (altered skin sensation), reported in 12.5% of the TRIUMPH-1 12 mg group versus 0.9% on placebo.

Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies and is contraindicated in patients with a personal or family history of MTC or MEN 2. Retatrutide has no label yet; its Phase 3 trials excluded people with that history.

Regulatory status defines who can actually access what#

This is the practical answer most readers care about, and it is unambiguous in late 2026.

Semaglutide 2.4 mg (Wegovy) is approved by the FDA and, through the European Commission's EU-wide authorization, in the EU and Norway for chronic weight management, with a full outcomes trial behind it. It is prescribed through licensed clinicians and dispensed through pharmacies.

Retatrutide is investigational. All four core TRIUMPH registrational trials have reported, and Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027 (Lilly, September 2026); approval timing then depends on the FDA review. This means anyone comparing the two peptides for a personal decision in 2026 is comparing an approved product to an investigational compound that Lilly says is legally available only to its trial participants, not two equal choices. Klarovel does not sell, stock or fulfill peptides, and any comparison content on the platform is protocol-layer editorial only. See the how it works page for our operating model.

For readers who want to model dosing arithmetic for either compound, the peptide calculator tool handles the reconstitution math.

The bottom line: two different tools, not two versions of the same thing#

Semaglutide is the mature, approved, cardiovascular-validated GLP-1 agonist. Retatrutide is the emerging triple agonist with roughly ten points more raw weight loss in cross-trial comparison and a striking liver-fat signal, but without the hard-outcomes dossier or regulatory approval that semaglutide already carries. The right comparison in 2026 is not "which is better" but "which one has the evidence base that matches the question being asked." For patients, that answer is still semaglutide today. For the research community tracking where obesity pharmacology is heading, retatrutide is the more consequential molecule to watch. Readers who want protocol-layer guidance grounded in primary literature can create a free Klarovel account to access the comparison tooling and structured trial summaries.